

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

KOIOS PHARMACEUTICALS LLC,  
Petitioner,

v.

MEDAC GESELLSCHAFT FÜR KLINISCHE  
SPEZIALPRÄPARATE MBH,  
Patent Owner.

---

Case IPR2016-01370  
Patent No. 8,664,231

---

**PETITIONER'S UPDATED EXHIBIT LIST**

**LIST OF EXHIBITS**

Exhibit 1001	U.S. 8,664,231 to Heiner Will, titled, "Concentrated Methotrexate Solutions," filed on March 4, 2009, and issued on March 4, 2014 ("the '231 Patent").
Exhibit 1002	Excerpts from File History for U.S. Patent No. 8,664,231.
Exhibit 1003	U.S. 6,544,504 to Paul Grint et al., titled, "Combined Use of Interleukin 10 and Methotrexate for Immunomodulatory Therapy," filed on June 26, 2000, and issued on April 8, 2003 (" <i>Grint</i> ").
Exhibit 1004	Hoekstra et al. (2004) J. Rheumatol. 31(4):645-47 (" <i>Hoekstra</i> ").
Exhibit 1005	Jørgensen et al. (1996) Ann. Pharmacother. 30:729-32 (" <i>Jørgensen</i> ").
Exhibit 1006	Alsufyani et al. (2003) J. Rheumatol. 31:179-82 (" <i>Alsufyani</i> ").
Exhibit 1007	Declaration of Dr. Elena Massarotti, dated June 2, 2016, in support of Medac's Preliminary Response in IPR2016-00649.
Exhibit 1008	Brooks et al. (1990) Arthritis and Rheum. 33(1):91-94 (" <i>Brooks</i> ").
Exhibit 1009	Medac's Preliminary Response in IPR2016-00649, dated June 2, 2016.
Exhibit 1010	Zackheim (1992) J. Am. Acad. of Derm. 23(6) p. 1008 (" <i>Zackheim</i> ").
Exhibit 1011	Müller-Ladner (2010) The Open Rheumatology Journal 4:15-22. (" <i>Müller-Ladner</i> ").
Exhibit 1012	Weinblatt Declaration; Dated June 17, 2014 ("Weinblatt Decl.").
Exhibit 1013	Gammon Declaration; Dated June 27, 2014 ("Gammon Decl.").
Exhibit 1014	Pincus et al. (2003) Clin. Exp. Rheumatol. (Suppl. 31):S179-S185 (" <i>Pincus</i> ").
Exhibit 1015	Insulin Administration, Diabetes Care, 26:1 S121-S124 (2003) (" <i>Insulin Admin</i> ").
Exhibit 1016	Complaint in <i>Medac Pharma, Inc. v. Antares Pharma, Inc.</i> , Nos. 1:14-cv-01498-JBS-KMW.
Exhibit 1017	Portion of EPO prosecution for EP Application No. 07 786 239.9 and Certified English Translation of the same.

Exhibit 1018	Weinblatt (1993) "Methotrexate," in Textbook of Rheumatology, 4th Edition, Chapter 47, (Kelley et al., eds. 1993) (" <i>Weinblatt 1993</i> ").
Exhibit 1019	Schiff et al., "Head-to-head, randomized, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis," <i>Ann. Rheum. Dis.</i> 0:1-3 (2014) (" <i>Schiff</i> ").
Exhibit 1020	Weinblatt (1995) Efficacy of Methotrexate in Rheumatoid Arthritis, <i>Br. J. Rheum.</i> 34(suppl. 2):43-48 (" <i>Weinblatt 1995</i> ").
Exhibit 1021	Product Label for the "Methotrexate Sodium for Injection" product by Wyeth, Date of First Authorization August 10, 1959, Date of Supplement Approval January 27, 2004, Obtained from Archive.org as of April 29, 2005 (" <i>Wyeth</i> "), and Internet Archive Affidavit.
Exhibit 1022	2003 Ed. of Physician's Desk Reference for "Methotrexate Sodium for Injection" by Wyeth (" <i>the PDR for Wyeth</i> ").
Exhibit 1023	Arthur et al. (2002) A Study of Parenteral Use of Methotrexate in Rheumatic Conditions, <i>J. Clinical Nursing</i> 2002; 11:256-63 (" <i>Arthur</i> ").
Exhibit 1024	Arthur et al. (2001) Self-Injection of Gold and Methotrexate, <i>J. Rheumatol.</i> 2001; 28(1):212 (" <i>Arthur 2001</i> ").
Exhibit 1025	Moitra et al. (2005) Caveats to the use of parenteral methotrexate in the treatment of rheumatic disease, <i>Rheumatology</i> 2005; 44:256-57 (" <i>Moitra</i> ").
Exhibit 1026	Product Label for "Methotrexate For Injection, USP" by Bigmar, Date of First Authorization February 26, 1999, Obtained from Archive.org as of February 16, 2005 (" <i>Bigmar</i> ").
Exhibit 1027	Feagan et al. (1995) Methotrexate for the Treatment of Crohn's Disease, <i>N. Engl. J. Med.</i> 332(5):292-97 (" <i>Feagan</i> ").
Exhibit 1028	Furst et al. (1989) Increasing Methotrexate Effect with Increasing Dose in the Treatment of Resistant Rheumatoid Arthritis, <i>J. Rheum.</i> 16(3):313-20 (" <i>Furst</i> ").
Exhibit 1029	Giannini et al. (1992) Methotrexate in resistant juvenile rheumatoid arthritis—results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. <i>N. Engl. J. Med.</i> 326(16):1043, 1045, 1048-49 (" <i>Giannini</i> ").
Exhibit 1030	[omitted]

Exhibit 1031	FDA Arthritis Advisory Committee.
Exhibit 1032	Results from Body Surface Area Calculator for Medication Doses (" <i>BSA Calculation</i> ").
Exhibit 1033	Miller Declaration and Curriculum Vitae ("Miller Decl.").
Exhibit 1034	Schiff Declaration and Curriculum Vitae ("Schiff Decl.").
Exhibit 1035	Noroozi Declaration ("Noroozi Decl.").
Exhibit 1036	Kamholz Declaration ("Kamholz Decl.").
Exhibit 1037	Second Kamholz Declaration
Exhibit 1038	Declaration of Kayvan B. Noroozi in Support of Motion for Admission <i>Pro Hac Vice</i>

Respectfully submitted,

/DeAnn F. Smith/

DeAnn F. Smith (Lead Counsel)  
Reg. No. 36,683  
FOLEY HOAG LLP  
155 Seaport West  
Boston, MA 02210  
dsmith@foleyhoag.com

William P. Rothwell (Back-Up Counsel)  
Reg. No. 72,522  
NOROOZI PC  
2245 Texas Drive, Suite 300  
Sugar Land, TX 77479  
william@noroozipc.com

*Counsel for Petitioner*

Date: August 18, 2017

**CERTIFICATION OF SERVICE**

The undersigned hereby certifies that the foregoing **PETITIONER'S  
UPDATED EXHIBIT LIST and new Exhibit 1038** was served electronically  
via e-mail on August 18, 2017, in its entirety on the following counsel of record  
for Patent Owner:

James F. Haley (Lead Counsel)	james.haley@hglaw.com
Brian Gummow (Back-up Counsel)	brian.gummow@hglaw.com
Service E-mail address	IPR2016-01370_Medac@ropesgray.com

Respectfully submitted,

/s/ William Rothwell

William P. Rothwell, Reg. No. 72,522  
NOROOZI PC  
2245 Texas Drive, Suite 300  
Sugar Land, TX 77479

*Counsel for Petitioner*

Date: August 18, 2017